| Filed On | Filing |
|---|---|
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition
Ironwood Pharmaceuticals Raises Full-Year 2026 Financial Guidance Driven by Continued LINZESS U.S. Net Sales Growth and Strong Third Quarter Financial Performance |
| 16 Oct 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
– Tom McCourt to Retire from CEO Post After 17 Years at Ironwood and Four Decades of Distinguished Industry Leadership Bringing Transformational Medicines to Patients – |
| 06 Aug 2026 |
8-K: Results of Operations and Financial Condition
– Raises full-year 2026 LINZESS® (linaclotide) U.S. net sales guidance to $1.15 - $1.20 billion, representing greater than 30% increase year-over-year; Raises total revenue guidance to $460 - $485 million and adjusted EBITDA guidance to ... |
| 18 Jun 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
This Amendment No. 1 (this “Amendment”) is made to the Amended and Restated 2019 Equity Incentive Plan (the “Plan”) of Ironwood Pharmaceuticals, Inc. (the “Company”). |
| 15 Jun 2026 |
8-K: Other Events
On June 15, 2026, Ironwood Pharmaceuticals, Inc. (the “Company”) repaid in full the $200.0 million aggregate principal amount of its 1.50% convertible senior notes due 2026 (the “2026 Convertible Notes”) at their scheduled maturity. The ... |
| 13 May 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On May 8, 2026, Gregory Martini notified Ironwood Pharmaceuticals, Inc. (the “Company”) that he is resigning from his position as Senior Vice President, Chief Financial Officer, effective May 15, 2026. Mr. Martini’s resignation is not du... |
| 07 May 2026 |
8-K: Results of Operations and Financial Condition
Ironwood Pharmaceuticals Reports Strong First Quarter 2026 Results with 97% year-over-year LINZESS U.S. Net Sales Growth; Maintains Full-Year 2026 Financial Guidance |
| 11 Mar 2026 |
8-K: Other Events
On March 10, 2026, Ironwood Pharmaceuticals, Inc. (the “Company”) notified Wells Fargo Bank, National Association, as administrative agent (in such capacity, the “Agent”), under the Credit Agreement, dated May 21, 2023, as amended by Ame... |
| 25 Feb 2026 |
8-K: Results of Operations and Financial Condition
Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Results; Achieves 2025 Financial Guidance and Reiterates Strong 2026 Outlook |
| 02 Jan 2026 |
8-K: Results of Operations and Financial Condition
- Expects full-year 2026 LINZESS® U.S. net sales of $1.125 to $1.175 billion; total revenues of $450 to $475 million and adjusted EBITDA of greater than $300 million - |
| 23 Dec 2025 |
8-K: Entry into a Material Definitive Agreement; Other Events
This Third Amendment to the Amended and Restated Exclusive License Agreement (this “Third Amendment”), dated as of December 18, 2025 (the “Amendment Effective Date”), is made and entered into by and among VectivBio AG, a corporation limi... |
| 26 Nov 2025 |
8-K: Other Events
On November 25, 2025, the U.S. Department of Health and Human Services released the “Maximum Fair Price” (“MFP”) for LINZESS® (linaclotide), which was selected in the most recent round of government price setting as part of the Inflation... |
| 10 Nov 2025 |
8-K: Results of Operations and Financial Condition
– LINZESS® (Iinaclotide) U.S. net sales of $315 million in Q3 2025, an increase of 40% year-over-year; EUTRx demand growth increased 12% year-over-year – |
| 10 Oct 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
On October 7, 2025, Andrew Dreyfus provided notice of his resignation from the Board of Directors of Ironwood Pharmaceuticals, Inc. (the “Company”), effective November 1, 2025. Mr. Dreyfus’ decision to resign is due to his appointment as... |
| 03 Sep 2025 |
8-K: Other Events
On August 29, 2025, Ironwood Pharmaceuticals, Inc. (the “Company”) received a letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it has regained compliance with the mini... |
| 07 Aug 2025 |
8-K: Results of Operations and Financial Condition
– LINZESS® (Iinaclotide) U.S. net sales of $248 million in Q2 2025; EUTRx demand growth of 10% year-over-year – |
| 10 Jul 2025 |
8-K: Changes in Registrant's Certifying Accountant
We have read Item 4.01 of Form 8-K dated July 10, 2025 of Ironwood Pharmaceuticals, Inc. and are in agreement with the statements contained in the first and third sentences of the first paragraph and second, third, fourth and fifth parag... |
| 12 Jun 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On June 10, 2025, Ironwood Pharmaceuticals, Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders (the “Annual Meeting”). The final voting results for the Annual Meeting are as follows: |
| 03 Jun 2025 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
On May 28, 2025, Ironwood Pharmaceuticals, Inc. (the “Company”) received a deficiency letter from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 c... |
| 07 May 2025 |
8-K: Results of Operations and Financial Condition
– On track to achieve FY 2025 financial guidance; raised adjusted EBITDA guidance to greater than $105 million for 2025 – |
Loading...